Salix Pharmaceuticals, Ltd. today announced the FDA has accepted for filing and designated for Priority Review the Company's New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE).
The details can be read here.
No comments:
Post a Comment